Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells
AssigneesFred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center
InventorsJarrod Dudakov, Marcel van den Brink, Enrico Velardi, Hans-Peter Kiem, Stefan Radtke, Scott James
Life of this patent
Estimating the term…
Abstract
The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.
Claims18
A cDNA comprising a sequence as set forth in SEQ ID NO:
- 19 or SEQ ID NO:
- 6 or a sequence having at least 90% sequence identity to SEQ ID NO:
- 19 or SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.